Mesoblast (NASDAQ:MESO) Shares Gap Down – Should You Sell?

Shares of Mesoblast Limited (NASDAQ:MESO) gapped down before the market opened on Wednesday . The stock had previously closed at $20.40, but opened at $19.08. Mesoblast shares last traded at $18.84, with a volume of 62,399 shares traded.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on MESO. Jefferies Financial Group lowered shares of Mesoblast from a “buy” rating to a “hold” rating in a research note on Monday, December 23rd. Cantor Fitzgerald upgraded shares of Mesoblast to a “strong-buy” rating in a report on Thursday, January 30th. Finally, Piper Sandler raised their target price on Mesoblast from $11.00 to $15.00 and gave the company an “overweight” rating in a report on Thursday, December 19th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Mesoblast currently has a consensus rating of “Moderate Buy” and a consensus price target of $13.50.

Mesoblast Stock Performance

The stock’s 50-day moving average is $16.33 and its 200-day moving average is $10.92. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.18 and a current ratio of 1.18.

Institutional Investors Weigh In On Mesoblast

Institutional investors and hedge funds have recently made changes to their positions in the company. R Squared Ltd acquired a new position in Mesoblast in the fourth quarter valued at about $30,000. Lindbrook Capital LLC boosted its holdings in shares of Mesoblast by 70.9% in the 4th quarter. Lindbrook Capital LLC now owns 2,172 shares of the company’s stock worth $43,000 after acquiring an additional 901 shares in the last quarter. Signaturefd LLC grew its position in Mesoblast by 128.7% during the 3rd quarter. Signaturefd LLC now owns 5,506 shares of the company’s stock worth $45,000 after acquiring an additional 3,099 shares during the last quarter. GAMMA Investing LLC increased its position in Mesoblast by 22.1% in the fourth quarter. GAMMA Investing LLC now owns 6,711 shares of the company’s stock worth $133,000 after purchasing an additional 1,213 shares during the period. Finally, China Universal Asset Management Co. Ltd. bought a new stake in Mesoblast during the 4th quarter worth about $134,000. Institutional investors and hedge funds own 1.43% of the company’s stock.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.